Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 5,456 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Malignancy Clear all
Completed Phase 1 Interventional

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

NCT00036777
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, 7-hydroxystaurosporine, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Oct 23, 2026, 9:21 PM EDT
Not yet recruiting Phase 2 Interventional

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

NCT07836101
View directory record Official record
Conditions
Any Advanced Solid Tumors
Interventions
Sarilumab, ICI Therapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Not applicable Interventional Results available

Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy

NCT00924651
View directory record Official record
Conditions
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
exercise
Behavioral
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years to 120 Years
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

NCT00567931
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
1-methyl-d-tryptophan, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Tampa, Florida • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 23, 2026, 9:21 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

NCT04305795
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Interventions
200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929 PIT
Biological · Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Miami, Florida • Lexington, Kentucky • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 23, 2026, 9:21 PM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Recruiting Phase 1 Interventional

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

NCT07356453
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
FORX-428
Drug
Lead sponsor
FoRx Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

NCT00810394
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Sorafenib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT03739931
View directory record Official record
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
mRNA-2752, Durvalumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
16
States / cities
San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 23, 2026, 9:21 PM EDT
Terminated Phase 1 Interventional

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02936102
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
Interventions
FAZ053, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

NCT01673737
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR260301, Vemurafenib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 23, 2026, 9:21 PM EDT
Terminated Phase 1 Interventional

Imaging and Biomarkers of Hypoxia in Solid Tumors

NCT01123005
View directory record Official record
Conditions
Neoplasms
Interventions
PET Scan, EF5, Carbogen, Dichloroacetate
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

Phase I Study of CPI-300 in Patients With Advanced Tumors

NCT04808453
View directory record Official record
Conditions
Advanced Tumors
Interventions
CPI-300
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Lake Mary, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 23, 2026, 9:21 PM EDT
Active, not recruiting Phase 4 Interventional

Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain

NCT04296305
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Hydromorphone, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Continuation Study of the Oral AKT Inhibitor GSK2110183

NCT01531894
View directory record Official record
Conditions
Cancer
Interventions
GSK2110183 (afuresertib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors

NCT06682039
View directory record Official record
Conditions
Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
Interventions
Internet-Based Intervention, Interview, Questionnaire Administration, Text Message-Based Navigation Intervention
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
15 Years to 29 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

NCT03700294
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ADCT-601
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

NCT05735366
View directory record Official record
Conditions
Solid Tumor
Interventions
SAIL66
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Gilbert, Arizona • Augusta, Georgia • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Terminated Phase 1 Interventional Results available

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

NCT04762602
View directory record Official record
Conditions
Isocitrate Dehydrogenase Gene Mutation
Interventions
HMPL-306
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT06915753
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, Locally Advanced Unresectable Hepatocellular Carcinoma
Interventions
TYRA-430
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

Study of Vemurafenib, Carboplatin, and Paclitaxel

NCT01636622
View directory record Official record
Conditions
Advanced Cancers
Interventions
Vemurafenib, Carboplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 23, 2026, 9:21 PM EDT
Terminated Phase 2 Interventional Results available

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

NCT02160041
View directory record Official record
Conditions
Solid Tumor, Hematologic Malignancies
Interventions
BGJ398
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Oceanside, California • San Francisco, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 23, 2026, 9:21 PM EDT
Recruiting Phase 1 Interventional

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NCT06400472
View directory record Official record
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Interventions
Sofe-M, bevacizumab, carboplatin, Itraconazole, pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

GW786034 in Treating Patients With Advanced Solid Tumors

NCT00060151
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pazopanib hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 23, 2026, 9:21 PM EDT